Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.47 |
| ▸ | CDK4 | P11802 | 7/20 | 0.47 |
| ▸ | CDK7 | P50613 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 3/20 | 0.42 |
| ▸ | CHUK | O15111 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411611 | 0.93 | IKBKB (0.49) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1411984 | 0.91 | CDK2 (0.53) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL3203537 | 0.91 | CDK2 (0.51) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL13486463 | 0.90 | CDC7 (0.47) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1412198 | 0.89 | CDK2 (0.50) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1411687 | 0.89 | EIF2AK2 (0.51) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1412209 | 0.89 | IKBKB (0.49) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1412063 | 0.88 | IKBKB (0.53) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1412075 | 0.88 | CDK2 (0.51) | CDK2CDK4CDK7CDK9CCNT1 | |
| SCHEMBL1411965 | 0.88 | CAMK2D (0.48) | CDK2CDK4CDK7CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | claimed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | claimed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| EP-1940846-B9 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LTD (GB) | 2012-09-12 | — | — | EP | disclosed |
| EP-1940846-B1 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-1940846-A2 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | Cyclacel Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYP2A13, NR1I3, NR3C2 | CDK2 577/4885CDK4 657/4885CDK7 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.